DeepHealth gains FDA approval for remote scanning in ultrasound
Addressing staffing challenges
The company's announcement comes as radiology workloads continue to rise, with the number of qualified technologists failing to keep pace. This disparity has contributed to staffing gaps and periods of MRI room closures, limiting access to complex scans and procedures for patients.
DeepHealth aims to address these issues by equipping technologists with the ability to operate scanning equipment for multiple locations remotely. This model enables improved operational efficiency and extends the scope of experienced staff to more cases across different centres.
Results from pilot study
During a pilot deployment at 64 RadNet sites in the New York area, DeepHealth's TechLive solution contributed to a 42 percent decrease in MRI room closure hours during the second quarter of 2025, compared with the same period in 2024. According to DeepHealth, this resulted in more timely scans for patients and improved access to complex procedures. The company has also reported that, through remote expert involvement, TechLive contributed to an increase in the number of complex imaging procedures performed at these locations.
The TechLive system currently connects over 300 RadNet MR, CT, PET/CT, and Ultrasound systems. By implementing real-time remote expertise, experienced senior sonographers and physicians can now guide on-site technologists through complex ultrasound cases - a modality noted for its reliance on operator skill and immediate decision-making.
Company perspectives "TechLive represents a paradigm shift in how we approach imaging operations. By enabling real-time remote expertise, we are not only addressing today's staffing challenges, we are creating a foundation for more efficient, financially sustainable, and high-quality patient care across the broadest set of imaging modalities. This FDA clearance validates DeepHealth's vision of a connected imaging ecosystem that scales human expertise beyond physical boundaries," said Sham Sokka, PhD, Chief Operating and Technology Officer at DeepHealth.
Operational impact
TechLive has been introduced to streamline imaging operations, with specific attention to enhancing operational efficiency, extending operating hours for centres, and improving access to more complex diagnostic and therapeutic procedures. The solution's extension to Ultrasound marks the first industry application of remote scanning and supervision for this modality.
By matching expert staff to complex cases in real time, DeepHealth seeks to increase patient throughput and maintain quality standards, while also helping care providers manage ongoing labour shortages and wage pressures in health services.
Sector implications
The increasing adoption of remote scanning solutions comes as healthcare providers face higher demand for complex imaging and persistent difficulty in recruiting qualified technologists. As radiology services evolve, solutions like TechLive are being considered as part of long-term strategies to maintain patient access and support a sustainable operational model.
Follow us on:
Share on:
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Techday NZ
2 days ago
- Techday NZ
DeepHealth gains FDA approval for remote scanning in ultrasound
DeepHealth has received FDA 510(k) clearance for its TechLive remote scanning solution, enabling centralised operations and supervision for MR, CT, PET/CT and, for the first time, Ultrasound procedures. Addressing staffing challenges The company's announcement comes as radiology workloads continue to rise, with the number of qualified technologists failing to keep pace. This disparity has contributed to staffing gaps and periods of MRI room closures, limiting access to complex scans and procedures for patients. DeepHealth aims to address these issues by equipping technologists with the ability to operate scanning equipment for multiple locations remotely. This model enables improved operational efficiency and extends the scope of experienced staff to more cases across different centres. Results from pilot study During a pilot deployment at 64 RadNet sites in the New York area, DeepHealth's TechLive solution contributed to a 42 percent decrease in MRI room closure hours during the second quarter of 2025, compared with the same period in 2024. According to DeepHealth, this resulted in more timely scans for patients and improved access to complex procedures. The company has also reported that, through remote expert involvement, TechLive contributed to an increase in the number of complex imaging procedures performed at these locations. The TechLive system currently connects over 300 RadNet MR, CT, PET/CT, and Ultrasound systems. By implementing real-time remote expertise, experienced senior sonographers and physicians can now guide on-site technologists through complex ultrasound cases - a modality noted for its reliance on operator skill and immediate decision-making. Company perspectives "TechLive represents a paradigm shift in how we approach imaging operations. By enabling real-time remote expertise, we are not only addressing today's staffing challenges, we are creating a foundation for more efficient, financially sustainable, and high-quality patient care across the broadest set of imaging modalities. This FDA clearance validates DeepHealth's vision of a connected imaging ecosystem that scales human expertise beyond physical boundaries," said Sham Sokka, PhD, Chief Operating and Technology Officer at DeepHealth. Operational impact TechLive has been introduced to streamline imaging operations, with specific attention to enhancing operational efficiency, extending operating hours for centres, and improving access to more complex diagnostic and therapeutic procedures. The solution's extension to Ultrasound marks the first industry application of remote scanning and supervision for this modality. By matching expert staff to complex cases in real time, DeepHealth seeks to increase patient throughput and maintain quality standards, while also helping care providers manage ongoing labour shortages and wage pressures in health services. Sector implications The increasing adoption of remote scanning solutions comes as healthcare providers face higher demand for complex imaging and persistent difficulty in recruiting qualified technologists. As radiology services evolve, solutions like TechLive are being considered as part of long-term strategies to maintain patient access and support a sustainable operational model. Follow us on: Share on:
NZ Herald
31-07-2025
- NZ Herald
Gisborne-based Mātai Institute secures $563k for meth and sports brain research
'With at least one in three Kiwis affected by a neurological condition in their lifetime, the work of these researchers is crucial to advancing healthcare and improving people's quality of life,' said the Neurological Foundation's head of research and acting chief executive, Dr Sarah Schonberger. Dr Sarah Schonberger is the head of research and acting chief executive of the Neurological Foundation. Schonberger acknowledged times were tough for Kiwi researchers. 'The need for innovation in healthcare and disease prevention is increasing at exactly the same time that investment is shrinking,' she said. 'We are so grateful that our generous supporters are able to make a real difference by helping fund bold, brilliant New Zealand research like Maryam and Josh's, which holds so much promise for important breakthroughs.' Schonberger said the international experts who reviewed the funding applications described them as timely and relevant. 'The research being done at Mātai is genuinely world-class. Kiwis are fortunate that we have such a great hub of excellence in Gisborne,' she said. Holdsworth said the institute was 'incredibly proud' to see Tayebi and McGeown recognised in the funding round. 'A huge thank you to the Neurological Foundation and its supporters for backing world-class science here in Tairāwhiti. 'We're also deeply grateful to the Hugh Green Foundation and the Fred Lewis Foundation – long-standing pillars of support, who, among others, have helped us reach this point in these projects.' The Neurological Foundation is the biggest non-government funder of neurological research in the country. McGeown received a further $3956 to attend the International Brain Injury Association (IBIA) World Congress. Mātai research projects receiving funding MRI biomarkers of brain recovery and treatment response in methamphetamine addiction: A longitudinal study Dr Maryam Tayebi Methamphetamine (meth) addiction is a huge problem affecting people's lives across New Zealand, with no effective medicines available yet. This project is investigating how meth addiction affects the brain and how it might heal during recovery. Using advanced MRI brain scans, researchers will track changes in the brains of people receiving treatment. The goal is to find signs that show who is likely to stay drug-free and who might relapse. By understanding how the brain recovers, doctors can better support people with meth addiction. This research could lead to more personalised treatments, making a big difference in how meth addiction is managed and helping more people successfully overcome addiction. Brain health in collision sports: Linking early-life changes to long-term clinical outcomes using multimodal neuroimaging Dr Joshua McGeown Many athletes in collision sports suffer repeated head impacts, which may lead to brain damage and higher risk for neurodegenerative disease. This damage is often 'invisible' because there is no noticeable bruising or swelling, and standard medical imaging doesn't show abnormalities. This research project uses clinical data and advanced brain scans from active and retired athletes to track how head impacts affect the brain over time. In collaboration with the Former Athlete Brain Health Research programme in Australia, this fellowship aims to understand whether early brain changes persist, progress, or recover. By studying active and retired athletes, the aim is to identify early signs of brain damage and develop better ways to prevent and treat injuries.
NZ Herald
30-07-2025
- NZ Herald
FDA pushes to restrict synthetic opioid derived from kratom leaf
'We think it's night and day in terms of the public health risk,' Makary said of 7-OH products. The agency is recommending to the Drug Enforcement Administration that 7-OH be classified as Schedule I, a tier designated to have no medical value and high risk of abuse. That tier still includes marijuana, which federal officials under the Biden Administration sought to move to a less restrictive category. That issue remains undecided. The law enforcement agency will review the 7-OH recommendation 'expeditiously', DEA Deputy Assistant Administrator Thomas Prevoznik said. Federal health officials rolled out the campaign to stamp out 7-OH with the nation still in the throes of a drug crisis fuelled by illicit fentanyl, methamphetamine, and other synthetic compounds easily manufactured in clandestine labs. Overdose deaths have dropped dramatically during the past year but still topped a staggering 80,000 in 2024. Health and Human Services Secretary Robert F. Kennedy jnr, who himself battled a heroin addiction decades ago, said that public health agencies have been 'asleep at the wheel' on previous crises of addiction in the US. The FDA's report presented scientific studies on 7-OH and advisories to consumers and doctors warning them of 'eye-catching' products sold as gummies, candies, and even ice-cream cones meant to appeal to young people. This month, the FDA said it had sent warning letters to seven companies regarding allegations that they illegally marketed 7-OH products as dietary supplements or unapproved drugs that touted relief from pain or anxiety. The scrutiny of 7-OH products adds another twist to the saga of kratom in the US. Amid the nation's drug crisis, kratom has become increasingly popular as users seek alternatives for pain or relief from opioid withdrawal symptoms. Smoke shops, service stations, convenience stores and online retailers across the US sell to devoted users who champion the health benefits of all-natural kratom products on social media. Speaking at the news conference today, kratom advocate Melody Woolf drew a distinction between the powdered kratom leaf she takes to ease her chronic pain and 7-OH products. Woolf said: '7-OH is not what helped me get out of bed and get the quality of life I enjoy'. Kratom acts as a mild stimulant when taken in small doses. Experts say that in higher doses, kratom's compounds can induce euphoria similar to opioids, though with less potency than many legal painkillers. One of kratom's many natural compounds is converted into the metabolite 7-OH, or 7-hydroxymitragynine, which produces an opioid-like effect in the brain. Though kratom contains trace amounts of the compound naturally, companies use semisynthetic 7-OH extracts to make an entirely new and potent product, said Christopher McCurdy, professor of medicinal chemistry at the University of Florida College of Pharmacy. 'This is essentially putting legal morphine at the gas station,' McCurdy said. Retailers have been slapped with wrongful-death lawsuits from families of people who died with kratom compounds in their blood, usually in conjunction with illicit drugs. In 2016, the Drug Enforcement Administration announced plans to classify kratom compounds as controlled substances but shelved the idea after a fierce backlash. More than a dozen states have passed laws regulating kratom, according to the American Kratom Association, a trade group representing the industry. The association casts companies selling 'enhanced' 7-OH products as bad actors that offer 'chemically manipulated' products – usually concentrated shots and tablets. The products distort the public's understanding of kratom and provide ammunition to critics who seek to ban plant products, said Mac Haddow, a spokesman and lobbyist for the association. 'We do not believe these products should be available over the counter,' Haddow said in an interview yesterday. An opposing trade association, the Holistic Alternative Recovery Trust, said the criticism is part of an 'intra-industry turf war' between companies losing market share and those making better products. 'Consumers find it more effective and safer,' Jeff Smith, the group's national policy director, said of such 7-OH products. Smith said the group supports measures such as warning labels, age restrictions and testing by third-party independent labs. But he criticised the FDA's proposals, saying officials presented no science to support the alleged dangers of 7-OH. He predicted a ban would push users to return to more dangerous substances and destroy responsible businesses. 'The public needs to speak up to prevent dramatic regulatory over-reach,' Smith said.
